Clinical trials: in Moldova
Ulcerative Colitis
A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of MK-6194 in participants with active UC.
- Trial name
- NCT04924114
- Testing
- MK-6194
- Where
- 17 sites in United States, Georgia and 6 more
- Volunteers
- 57 people
- Sponsor
- Merck Sharp & Dohme LLC
Epilepsy
A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment
The purpose of the study is to assess the long-term use of lacosamide oral solution dosed at 2 mg/kg/day to 12 mg/kg/day when administered to pediatric study participants with epilepsy who have completed NCT01964560 (EP0034) or…
- Trial name
- NCT04627285
- Testing
- Lacosamide
- Where
- 15 sites in Georgia, Hungary and 4 more
- Volunteers
- 48 people
- Sponsor
- UCB Biopharma SRL
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
The purpose of the study is to determine the recommended Phase 2 dose(s) (RP2D[s]) in B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) in Part 1 and to evaluate the safety of JNJ-64264681 at the RP2D(s) in…
- Trial name
- NCT04210219
- Testing
- JNJ-64264681
- Where
- 15 sites in United States, Georgia and 5 more
- Volunteers
- 85 people
- Sponsor
- Janssen Research & Development, LLC
Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
The primary purpose of this study is to determine: the recommended Phase 2 doses (RP2Ds) of JNJ-64264681 and JNJ 67856633 when administered together in participants with B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic…
- Trial name
- NCT04657224
- Testing
- JNJ-64264681, JNJ-67856633
- Where
- 28 sites in United States, Australia and 10 more
- Volunteers
- 75 people
- Sponsor
- Janssen Research & Development, LLC
Non-Small Cell Lung Cancer
A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer
This is a Phase 1, open-label, multicenter, multiple-dose study to evaluate aumolertinib in European participants with a confirmed diagnosis of activating EGFR mutation positive (EGFRm+) locally advanced or metastatic NSCLC.
- Trial name
- NCT07130916
- Testing
- Aumolertinib
- Where
- 6 sites in Bosnia and Herzegovina, Bulgaria and 1 more
- Volunteers
- 20 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Acute Schizophrenia, Schizoaffective Disorder
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
- Trial name
- REFRESH (NCT01490086)
- Testing
- RP5063, aripiprazole
- Where
- 15 sites in United States, India and 3 more
- Volunteers
- 234 people
- Sponsor
- Reviva Pharmaceuticals
Chronic Hepatitis B
A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus Infection
This is a randomized, blinded, placebo-controlled, dose-ranging Phase 1b study of the safety, PK, and antiviral activity of ABI-4334 in treatment-naïve or off-treatment chronic Hepatitis B virus (cHBV) subjects that are Hepatitis…
- Trial name
- NCT06384131
- Testing
- ABI-4334
- Where
- 2 sites in Moldova, New Zealand
- Volunteers
- 20 people
- Sponsor
- Assembly Biosciences
Crohn Disease
VTX958 for the Treatment of Moderately to Severely Active Crohn's Disease
This is a multicenter, randomized, double-blind placebo-controlled, parallel group study to evaluate the efficacy and safety of VTX958 in participants with moderately to severely active Crohn's Disease.
- Trial name
- Harmony-CD (NCT05688852)
- Testing
- VTX958
- Where
- 105 sites in United States, Australia and 13 more
- Volunteers
- 107 people
- Sponsor
- Ventyx Biosciences, Inc
Pulmonary Arterial Hypertension
A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002)
This study of frespaciguat in participants with Group 1 pulmonary arterial hypertension (PAH) will assess the safety, tolerability and pharmacokinetics (PK) of inhaled frespaciguat. There is no formal hypothesis to be tested.
- Trial name
- NCT03744637
- Testing
- Frespaciguat
- Where
- Moldova
- Volunteers
- 25 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)
The purpose of this study is to assess the safety and efficacy of Rodatristat Ethyl in pulmonary arterial hypertension (PAH) patients.
- Trial name
- NCT04712669
- Testing
- rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID
- Where
- 64 sites in United States, Austria and 15 more
- Volunteers
- 108 people
- Sponsor
- Altavant Sciences GmbH
Pulmonary Hypertension
Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)
The primary objectives of this study are to assess the safety/tolerability and efficacy (by evaluating changes in pulmonary vascular resistance [PVR] and pulmonary blood volume [PBV]) of frespaciguat in participants with…
- Trial name
- NCT04370873
- Testing
- Frespaciguat
- Where
- 9 sites in United States, Israel and 1 more
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis
The purpose of this study is to evaluate safety and tolerability of JNJ-67484703 administrations in participants with active rheumatoid arthritis (RA).
- Trial name
- NCT04985812
- Testing
- JNJ-67484703
- Where
- 11 sites in United States, Georgia and 4 more
- Volunteers
- 44 people
- Sponsor
- Janssen Research & Development, LLC
Opioid-use Disorder, HIV Infections
Project MATLINK: Development and Evaluation of a Screening, Brief Intervention, & Referral to Treatment (SBIRT) Program for Opioid Dependent Prisoners and Probationers Transitioning to the Community
The purpose of this study is to evaluate the efficacy a Screening, Brief Intervention, and Referral to Treatment (SBIRT) program for linking opioid dependent individuals currently incarcerated or in probation in Moldova…
- Conditions
- Opioid-use Disorder, HIV Infections, Tuberculosis, Hepatitis C
- Trial name
- MATLINK (NCT04947475)
- Testing
- SBIRT
- Where
- 3 sites in Kyrgyzstan, Moldova and 1 more
- Volunteers
- 835 people
- Sponsor
- Yale University
Depressive Disorder, Anxiety
An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress
The purpose of this study is to evaluate the efficacy and safety and tolerability of JNJ-42165279 in participants with major depressive disorder (MDD) with anxiety symptoms who have had inadequate response to treatment with a…
- Trial name
- NCT02498392
- Testing
- JNJ-42165279
- Where
- 32 sites in United States, Moldova and 4 more
- Volunteers
- 161 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression
The purpose of this study is to evaluate the efficacy of JNJ-67953964 compared to placebo when administered as adjunctive treatment in participants with Major Depressive Disorder (MDD) partially responsive to selective serotonin…
- Trial name
- NCT03559192
- Testing
- JNJ-67953964
- Where
- 53 sites in United States, Germany and 4 more
- Volunteers
- 181 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder With Anxious Distress
A Study of JNJ-61393215 in the Treatment of Depression
The purpose of this study is to evaluate the efficacy of JNJ-61393215 as adjunctive treatment compared to adjunctive placebo, as assessed by the change from baseline to week 6 on a 17-item Hamilton Depression Rating Scale…
- Trial name
- NCT04080752
- Testing
- JNJ-61393215
- Where
- 35 sites in United States, Moldova and 3 more
- Volunteers
- 222 people
- Sponsor
- Janssen Research & Development, LLC
Systemic Lupus Erythematosus
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus
This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mosunetuzumab in participants with systemic lupus erythematosus (SLE).
- Trial name
- NCT05155345
- Testing
- Mosunetuzumab, Tocilizumab
- Where
- 3 sites in United States, Moldova and 1 more
- Volunteers
- 15 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma, Cirrhosis
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy.
- Trial name
- LIVERATION (NCT05201404)
- Testing
- Namodenoson
- Where
- 32 sites in United States, Bosnia and Herzegovina and 7 more
- Volunteers
- 471 people
- Sponsor
- Can-Fite BioPharma
Gastrointestinal Neoplasms, Adenocarcinoma
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
The Phase 1b study is an open-label, multicenter dose escalation study designed to assess the safety, tolerability, immunogenicity and recommended phase 2 dose (RP2D) of IMU-131.
- Trial name
- NCT02795988
- Testing
- IMU-131, Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.
- Where
- 22 sites in Georgia, India and 5 more
- Volunteers
- 64 people
- Sponsor
- Imugene Limited
Monitoring, Immunologic, Active Tuberculosis
New Generation IGRA in Immunocompromised Individuals
Evaluation of a new ELISA based interferon-gamma release assay (QuantiFERON TB plus In-tube test) in immunocompromized patients
- Conditions
- Monitoring, Immunologic, Active Tuberculosis, Tuberculosis in Solid Organ Transplant Recipients, Tuberculosis in Marrow Transplant Recipients
- Trial name
- TBnet#54 (NCT02639936)
- Where
- 16 sites in Denmark, Germany and 8 more
- Volunteers
- 2,663 people, healthy volunteers welcome
- Sponsor
- Tuberculosis Network European Trialsgroup